Efficacy of a Novel Pancreatic Enzyme Product, EUR-1008 (Zenpep), in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis

Pancreas ◽  
2011 ◽  
Vol 40 (3) ◽  
pp. 376-382 ◽  
Author(s):  
Phillip P. Toskes ◽  
Angelo Secci ◽  
Ruth Thieroff-Ekerdt
2001 ◽  
Vol 15 (2) ◽  
pp. 127-130 ◽  
Author(s):  
Mary Anne Cooper ◽  
Aubrey Groll

A 14-year-old child treated with valproic acid over several years for a seizure disorder developed abdominal pain with radiological evidence of acute pancreatitis. The association with valproic acid was not recognized, and the child continued to take the drug. The patient eventually developed steatorrhea and weight loss that improved with pancreatic enzyme replacement. Radiological evaluation showed an atrophic pancreas. Without evidence of other etiological factors, valproic acid by itself appeared to be the cause of chronic pancreatitis with exocrine pancreatic insufficiency in this patient.


2016 ◽  
Vol 53 (2) ◽  
pp. 94-97 ◽  
Author(s):  
Anna Victoria FRAGOSO ◽  
Martha Regina PEDROSO ◽  
Paulo HERMAN ◽  
André Luis MONTAGNINI

ABSTRACT Background - Among late postoperative complications of pancreatectomy are the exocrine and endocrine pancreatic insufficiencies. The presence of exocrine pancreatic insufficiency imposes, as standard treatment, pancreatic enzyme replacement. Patients with chronic pancreatitis, with intractable pain or any complications with surgical treatment, are likely to present exocrine pancreatic insufficiency or have this condition worsened requiring adequate dose of pancreatic enzymes. Objective - The aim of this study is to compare the required dose of pancreatic enzyme and the enzyme replacement cost in post pancreatectomy patients with and without chronic pancreatitis. Methods - Observational cross-sectional study. In the first half of 2015 patients treated at the clinic of the Department of Gastrointestinal Surgery at Hospital das Clínicas, Universidade de São Paulo, Brazil, who underwent pancreatectomy for at least 6 months and in use of enzyme replacement therapy were included in this series. The study was approved by the Research Ethics Committee. The patients were divided into two groups according to the presence or absence of chronic pancreatitis prior to pancreatic surgery. For this study, P<0.05 was considered statistically significant. Results - The annual cost of the treatment was R$ 2150.5 ± 729.39; R$ 2118.18 ± 731.02 in patients without pancreatitis and R$ 2217.74 ± 736.30 in patients with pancreatitis. Conclusion - There was no statistically significant difference in the cost of treatment of enzyme replacement post pancreatectomy in patients with or without chronic pancreatitis prior to surgical indication.


2008 ◽  
Vol 134 (4) ◽  
pp. A-583-A-584 ◽  
Author(s):  
James E. Heubi ◽  
Steven R. Boas ◽  
Kathryn Blake ◽  
Abdel Rahman H. Nasr ◽  
Marlyn S. Woo ◽  
...  

2021 ◽  
Vol 10 (24) ◽  
pp. 5779
Author(s):  
Lumír Kunovský ◽  
Petr Dítě ◽  
Petr Jabandžiev ◽  
Michal Eid ◽  
Karolina Poredská ◽  
...  

Exocrine pancreatic insufficiency (EPI), an important cause of maldigestion and malnutrition, results from primary pancreatic disease or is secondary to impaired exocrine pancreatic function. Although chronic pancreatitis is the most common cause of EPI, several additional causes exist. These include pancreatic tumors, pancreatic resection procedures, and cystic fibrosis. Other diseases and conditions, such as diabetes mellitus, celiac disease, inflammatory bowel disease, and advanced patient age, have also been shown to be associated with EPI, but the exact etiology of EPI has not been clearly elucidated in these cases. The causes of EPI can be divided into loss of pancreatic parenchyma, inhibition or inactivation of pancreatic secretion, and postcibal pancreatic asynchrony. Pancreatic enzyme replacement therapy (PERT) is indicated for the conditions described above presenting with clinically clear steatorrhea, weight loss, or symptoms related to maldigestion and malabsorption. This review summarizes the current literature concerning those etiologies of EPI less common than chronic pancreatitis, the pathophysiology of the mechanisms of EPI associated with each diagnosis, and treatment recommendations.


2020 ◽  
Vol 16 (30) ◽  
pp. 56-64
Author(s):  
A.I. Levchenko ◽  
◽  
Yu.V. Osipenko ◽  
Yu.A. Kucheryavy ◽  
D.S. Bordin ◽  
...  

Bacterial overgrowth syndrome (BOS) is characterized by clinical symptoms similar to those of exocrine pancreatic insufficiency (EPI) in chronic pancreatitis (CP). This phenomenon complicates differential diagnosis, especially when BOS and CP combined with EPI. BOS can contribute to the development of malabsorption and impaired digestion. As a result, it occurs diarrhea, steatorrhea, the lack of fat-soluble vitamins, as well as bloating and weight loss can be noticed. Pancreatic enzyme deficiency, alcohol abuse, use of narcotic analgesics to relieve abdominal pain, and proton pump inhibitors (PPIS) that cause drug hypochlohydria are predictors of the weakening of the gastroduodenal antibacterial barrier, and therefore potential risk factors for the development of BOS in CP, especially complicated by EPI. The lack of standard protocols and unified diagnostic methods does not provide the complete picture of the incidence of BOS in CP, and the available data are contradictory and heterogeneous. However, the verification of BOS in CP and way to correct it requires further research. Standardization of research methods and interpretation of results will allow implementing more specific and targeted treatment


2018 ◽  
pp. 109-113
Author(s):  
O. N. Minushkin ◽  
L. V. Maslovsky ◽  
A. E. Evsikov ◽  
A. M. Chebotareva

The article presents a review of current European and Russian guidelines on diagnostics and treatment of exocrine pancreatic insufficiency in patients with chronic pancreatitis. Results of our own comparative study on treatment of 55 chronic pancreatitis patients with low and adequate doses of pancreatic enzyme replacement therapy (PERT) confirm the need for usage of recommended doses of modern micronized polyenzyme drugs since it improves both clinical manifestation and nutritional status in such patients unlike the lower doses. Our research findings show that the optimal criterium for PERT efficacy assessment is the normalization of antropometric and biochemical nutritional markers.


Sign in / Sign up

Export Citation Format

Share Document